Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication
Abstract Background The treatment of Ewing sarcoma, an aggressive bone and soft tissue sarcoma, is associated with suboptimal outcomes and significant side-effects. Consequently, there is an urgent need to identify novel therapies that will improve outcomes for children and adults with Ewing sarcoma...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-11-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-020-07668-6 |
| _version_ | 1818620372664188928 |
|---|---|
| author | Torin Waters Kelli L. Goss Stacia L. Koppenhafer William W. Terry David J. Gordon |
| author_facet | Torin Waters Kelli L. Goss Stacia L. Koppenhafer William W. Terry David J. Gordon |
| author_sort | Torin Waters |
| collection | DOAJ |
| description | Abstract Background The treatment of Ewing sarcoma, an aggressive bone and soft tissue sarcoma, is associated with suboptimal outcomes and significant side-effects. Consequently, there is an urgent need to identify novel therapies that will improve outcomes for children and adults with Ewing sarcoma tumors while also decreasing treatment-related toxicities. Methods We analyzed data from the PRISM drug repurposing screen, which tested the activity of 4518 drugs across 578 cancer cell lines, to identify drugs that selectively inhibit the growth of Ewing sarcoma cell lines. We then tested the effects of a top hit from the screen on cell proliferation, cell cycle progression, and activation of the DNA damage pathway using Ewing sarcoma cell lines. We also used a CRISPR/Cas9 gene knockout approach to investigate the role of Schlafen 11 (SLFN11), a restriction factor for DNA replication stress that is overexpressed in Ewing sarcoma tumors, in mediating the sensitivity of Ewing sarcoma cells to the drug. Results We found that eltrombopag, an FDA-approved thrombopoietin-receptor agonist (TPO-RA) that is currently being evaluated as a treatment for chemotherapy-induced thrombocytopenia, inhibits the growth of Ewing sarcoma cell lines in vitro in proliferation and colony formation assays. However, from a mechanistic standpoint, the thrombopoietin receptor is not expressed in Ewing sarcoma cells and we show that eltrombopag impairs DNA replication and causes DNA damage in Ewing sarcoma cells by chelating iron, a known “off-target” effect of the drug. We also found that the sensitivity of Ewing sarcoma cells to eltrombopag is mediated, in part, by SLFN11, which regulates the cellular response to DNA replication stress. Conclusions Ewing sarcoma cell lines are sensitive to eltrombopag and this drug could improve outcomes for patients with Ewing sarcoma tumors by both targeting the tumor, via chelation of iron and inhibition of DNA replication, and reducing chemotherapy-induced thrombocytopenia, via stimulation of the thrombopoietin receptor. |
| first_indexed | 2024-12-16T17:52:20Z |
| format | Article |
| id | doaj.art-c6df154561694243885a70d3e046906f |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-16T17:52:20Z |
| publishDate | 2020-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-c6df154561694243885a70d3e046906f2022-12-21T22:22:16ZengBMCBMC Cancer1471-24072020-11-0120111110.1186/s12885-020-07668-6Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replicationTorin Waters0Kelli L. Goss1Stacia L. Koppenhafer2William W. Terry3David J. Gordon4Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of IowaDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, University of IowaDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, University of IowaDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, University of IowaDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, University of IowaAbstract Background The treatment of Ewing sarcoma, an aggressive bone and soft tissue sarcoma, is associated with suboptimal outcomes and significant side-effects. Consequently, there is an urgent need to identify novel therapies that will improve outcomes for children and adults with Ewing sarcoma tumors while also decreasing treatment-related toxicities. Methods We analyzed data from the PRISM drug repurposing screen, which tested the activity of 4518 drugs across 578 cancer cell lines, to identify drugs that selectively inhibit the growth of Ewing sarcoma cell lines. We then tested the effects of a top hit from the screen on cell proliferation, cell cycle progression, and activation of the DNA damage pathway using Ewing sarcoma cell lines. We also used a CRISPR/Cas9 gene knockout approach to investigate the role of Schlafen 11 (SLFN11), a restriction factor for DNA replication stress that is overexpressed in Ewing sarcoma tumors, in mediating the sensitivity of Ewing sarcoma cells to the drug. Results We found that eltrombopag, an FDA-approved thrombopoietin-receptor agonist (TPO-RA) that is currently being evaluated as a treatment for chemotherapy-induced thrombocytopenia, inhibits the growth of Ewing sarcoma cell lines in vitro in proliferation and colony formation assays. However, from a mechanistic standpoint, the thrombopoietin receptor is not expressed in Ewing sarcoma cells and we show that eltrombopag impairs DNA replication and causes DNA damage in Ewing sarcoma cells by chelating iron, a known “off-target” effect of the drug. We also found that the sensitivity of Ewing sarcoma cells to eltrombopag is mediated, in part, by SLFN11, which regulates the cellular response to DNA replication stress. Conclusions Ewing sarcoma cell lines are sensitive to eltrombopag and this drug could improve outcomes for patients with Ewing sarcoma tumors by both targeting the tumor, via chelation of iron and inhibition of DNA replication, and reducing chemotherapy-induced thrombocytopenia, via stimulation of the thrombopoietin receptor.https://doi.org/10.1186/s12885-020-07668-6Ewing sarcomaEltrombopagIron chelation |
| spellingShingle | Torin Waters Kelli L. Goss Stacia L. Koppenhafer William W. Terry David J. Gordon Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication BMC Cancer Ewing sarcoma Eltrombopag Iron chelation |
| title | Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication |
| title_full | Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication |
| title_fullStr | Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication |
| title_full_unstemmed | Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication |
| title_short | Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication |
| title_sort | eltrombopag inhibits the proliferation of ewing sarcoma cells via iron chelation and impaired dna replication |
| topic | Ewing sarcoma Eltrombopag Iron chelation |
| url | https://doi.org/10.1186/s12885-020-07668-6 |
| work_keys_str_mv | AT torinwaters eltrombopaginhibitstheproliferationofewingsarcomacellsviaironchelationandimpaireddnareplication AT kellilgoss eltrombopaginhibitstheproliferationofewingsarcomacellsviaironchelationandimpaireddnareplication AT stacialkoppenhafer eltrombopaginhibitstheproliferationofewingsarcomacellsviaironchelationandimpaireddnareplication AT williamwterry eltrombopaginhibitstheproliferationofewingsarcomacellsviaironchelationandimpaireddnareplication AT davidjgordon eltrombopaginhibitstheproliferationofewingsarcomacellsviaironchelationandimpaireddnareplication |